Your browser doesn't support javascript.
loading
A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 389-394, 2019.
Article in Chinese | WPRIM | ID: wpr-775615
ABSTRACT
Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibitors of programmed death-1 and programmed death-ligand 1. Preclinical studies have shown that ICIPs have shown good clinical efficacy and durable response in diverse cancers. Among them, atezolizumab (MPDL3280), an anti-PD-L1 monoclonal antibody, is being investigated as a potential therapy against solid tumors and hematologic malignancies in humans. Pseudoprogression is reported as one of the unique phenomena with immune therapeutic agents. Here we report case of a person with advanced NSCLC who developed pseudoprogression after receiving immunotherapy. We hope this case could help clinicians to make appropriate decision when assessing therapeutic effects of immunotherapy.
.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Diagnostic Imaging / Carcinoma, Non-Small-Cell Lung / Drug Therapy / Antineoplastic Agents, Immunological / Immunotherapy / Lung Neoplasms / Antibodies, Monoclonal Type of study: Diagnostic study / Prognostic study Limits: Humans / Male Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2019 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Diagnostic Imaging / Carcinoma, Non-Small-Cell Lung / Drug Therapy / Antineoplastic Agents, Immunological / Immunotherapy / Lung Neoplasms / Antibodies, Monoclonal Type of study: Diagnostic study / Prognostic study Limits: Humans / Male Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2019 Type: Article